Abstract. Failure in regulation of genes involved in growth and division of cells may result in pathological conditions, particularly cancer. Regulation is exerted at various levels of the transcriptional and post-transcriptional processes involving mainly nucleic acid-binding proteins. Here, we systematically explored the proteome of ten different cell lines in search for proteins potentially serving as molecular markers and/or targets for monitoring prognostic outcome and clinical therapies. Highthroughput analysis, two-dimensional electrophoresis coupled to matrix-assisted laser desorption/ionization mass spectrometry, identified 72 nucleotide-binding proteins and their interacting partners, which were differentially expressed in the cell lines investigated. Out of the 72 identified proteins, 33 of them were specifically expressed in a single cell line (for e.g., replication protein A 32 kDa, transcription intermediary factor 1, heterogeneous ribonucleoproteins). Moreover, tumor-related proteins including breast carcinoma amplified sequence 2, zinc finger proteins, chromobox protein homologs were identified in individual cell lines. The present findings demonstrate that rich protein information can be obtained by means of proteomic analysis for better understanding of oncogenesis and pathogenesis in a global way, which in turn represents the basis for the rational designs of diagnostic and therapeutic methods.
Introduction
In living systems, proteins, nucleic acids and other biomacromolecules within the cellular milieu interact with each other, thereby exhibiting various biological activities. The interaction of proteins with nucleic acids by and large is central to many cellular functions. Precisely regulated gene expression is a prerequisite for producing and maintaining the many different types of cells and tissues of a multicellular organism. Control of gene expression can be exerted at the transcription level at promoters and other DNA sequences outside the coding region. Post-transcriptional regulation is, however, the predominant regulatory mechanism for gene expression in eukaryotes. It can involve control of RNA splicing, transport, stability, localization and translation in a temporally and spatially regulated manner, allowing cells of different types or at different developmental stages to fine-tune their pattern of gene expression (1, 2) . These controls are mediated via interactions between regulatory DNA/RNA sequences and nucleic acid recognition motifs of a protein (3) . Nucleic acidbinding proteins are modular in structure with conserved nucleic acid binding domains and auxiliary domains that function in the assembly of multiprotein complexes central to specific functions (2, 4, 5) . Whilst some domains specifically recognize RNA or DNA, others recognize both DNA and RNA. Domains for DNA recognition include among others zinc finger, leucine zipper, helix-turn-helix, helix-loop-helix, POU and KH domains. Several motifs have also been identified for RNA-binding proteins and the list includes, but is not limited to the RNP domain (also called RNA recognition motif, RRM), the RGG box, zinc fingers, KH domain, double strand RNA-binding motif (DSRM) and the oligonucleotide/oligosaccharide binding motif (OB fold). The adaptation of a nucleic acid recognition motif to different purposes in different contexts is of importance both from functional and evolutionary perspectives.
Cancer is a disorder of cells and although it usually appears as a tumor made up of a mass of cells, the visible tumor is the end result of a whole series of changes which may have taken many years to develop. The behavior patterns of many tumors, and in some cases even the causal agents, are known, but how these agents transformed normal cells and influenced tumor cell behavior is beginning to be elucidated. The development of molecular biology opened up a major new approach to the molecular analysis of normal and tumor cells. Particularly, rapid advances in proteomic studies have greatly increased our understanding of the complex interactions of proteins within the cellular environment. The dynamic nature of the proteome of a cell or a tissue provides ample justification for studying gene expression in disease states at the protein level. There is growing interest in applying proteomics to gain insight into disease processes, develop Sample preparation. Harvested cells were washed three times with 10 ml phosphate-buffered saline (Gibco BRL, Gaithersburg, MD, USA) and centrifuged for 10 min at 800 x g at room temperature. The supernatant was discarded and the pellet was homogenized with 1.0 ml of sample buffer consisting of 40 mM Tris, 7 M urea (Merck, Germany), 2 M thiourea (Sigma, St. Louis, MO, USA), 4% CHAPS (3-[(3-cholamidopropyl) dimethylammonio]-1-propane-sulfonate) (Sigma, St. Louis, MO, USA), 65 mM 1,4-dithioerythritol (Merck), 1 mM EDTA (Merck) and protease inhibitors complete (Roche, Basel, Switzerland). After homogenization samples were left at room temperature for 1 h and centrifuged at 14,000 rpm for 1 h and supernatant was transferred into Ultrafree-4 centrifugal filter unit (Millipore, Bedford, MA), for desalting and concentrating proteins. Protein content of the supernatant was quantified by Bradford protein assay method (6) . The standard curve was generated using bovine serum albumin and absorbance was measured at 595 nm. . Samples prepared from each cell line were subjected to 2-DE as described elsewhere (7) . Protein (1 mg) was applied on immobilized pH 3-10 non-linear gradient strips in sample cups at their basic and acidic ends. Focusing was started at 200 V and the voltage was gradually increased to 8,000 V at a rate of 4 V/ min and then kept constant for a further 3 h (approximately 150,000 V/h totally). After the first dimension, strips (13 cm) were equilibrated for 15 min in a buffer containing 6 M urea, 20% glycerol, 2% sodium dodecylsulfate, 2% 1,4-dithioerythritol and then for 15 min in the same buffer containing 2.5% iodoacetamide instead of 1,4-dithioerythritol. After equilibration, strips were loaded onto 9-16% gradient sodium dodecylsulfate polyacrylamide gels for second-dimensional separation. Gels (180x200x1.5 mm) and run at 40 mA per gel. Immediately after the second dimension run, gels were fixed for 12 h in 50% methanol, containing 10% phosphoric acid and stained with Colloidal Coomassie blue (Novex, San Diego, CA) for 12 h on a rocking shaker. Molecular masses were determined by running standard protein markers (Bio-Rad), covering the range 10-250 kDa. pI values were used as given by the supplier of the immobilized pH gradient strips (Amersham Bioscience, Uppsala, Sweden). Excess of dye was washed out from the gels with distilled water and were scanned with ImageScanner (Amersham Pharmacia Biotech). Electronic images of gels were recorded using Adobe Photoshop and Microsoft PowerPoint Softwares.
Two-dimensional gel electrophoresis

Matrix-assisted laser desorption ionization mass spectrometry (MALDI/MS).
Spots were excised with a spot picker (PROTEINEER sp™, Bruker Daltonics, Germany), placed into 96-well microtiter plates and in-gel digestion and sample preparation for MALDI analysis were performed by an automated procedure (PROTEINEER dp™, Bruker Daltonics) (8, 9) . Briefly, spots were excised and washed with 10 mM ammonium bicarbonate and 50% acetonitrile in 10 mM ammonium bicarbonate. After washing, gel plugs were shrunk by addition of acetonitrile and dried by blowing out the liquid through the pierced well bottom. The dried gel pieces were reswollen with 40 ng/μl trypsin (Roche Diagnostics, Penzberg, Germany) in enzyme buffer [consisting of 5 mM Octyl ß-D-glucopyranoside (OGP) and 10 mM ammonium bicarbonate] and incubated for 4 h at 30˚C. Peptide extraction was performed with 10 μl of 1% TFA in 5 mM OGP. Extracted peptides were directly applied onto a target (AnchorChip™, Bruker Daltonics) that was load with ·-cyano-4-hydroxycinnamic acid (Bruker Daltonics) matrix thinlayer. The mass spectrometer used in this work was an Ultraflex™ TOF/ TOF (Bruker Daltonics) operated in the reflector for MALDI-TOF peptide mass fingerprint (PMF) or LIFT mode for MALDI-TOF/TOF with a fully automated mode using the Table I. Identification of investigated cell lines (ATCC).  -------------------------------------------------Name  ATCC no.  Cancer type   -------------------------------------------------Saos-2  HTB-85  Osteosarcoma  SK-N-SH  HTB-11  Neuroblastoma  HCT116  CCL-247  Colorectal carcinoma  CaOva3  HTB-75  Adenocarcinoma of ovary  A-549  CCL-185  Alveolar cell carcinoma of lung  HL-60  CCL-240  Promyeolcytic leukemia  A-673  CRL-1598  Rhabdomyosarcoma  A-375  CRL-1619  Malignant melanoma  MCF-7  HTB-22  Adenocarcinoma of mammary gland  HeLa  CCL-2 Adenocarcinoma of cervix . Each spectrum was produced by accumulating data from 200 consecutive laser shots. Those samples which were analyzed by PMF from MALDI-TOF were additionally analyzed using LIFT-TOF/TOF MS/MS from the same target. A maximum of three precursor ions per sample were chosen for MS/MS analysis. In the TOF1 stage, all ions were accelerated to 8 kV under conditions promoting metastable fragmentation. After selection of jointly migrating parent and fragment ions in a timed ion gate, ions were lifted by 19 kV to high potential energy in the LIFT cell. After further acceleration of the fragment ions in the second ion source, their masses could be simultaneously analyzed in the reflector with high sensitivity. PMF and LIFT spectra were interpreted with the Mascot software (Matrix Science Ltd., London, UK). Database searches, through Mascot, using combined PMF and MS/MS datasets were performed via BioTools 2.2 software (Bruker). A mass tolerance of 100 ppm and 2 missing cleavage sites for PMF and MS/MS tolerance of 0.5 Da and 1 missing cleavage sites for MS/MS search were allowed and oxidation of methionine residues was considered. The probability score calculated by the software was used as criterion for correct identification.
The algorithm used for determining the probability of a false positive match with a given mass spectrum is described elsewhere (10) . or MS/MS following in-gel trypsinization and identification was carried out by matching the peptide mass with the theoretical peptide mass of all proteins in the SWISS-PROT database. Internal standards were used to correct the measured peptide mass, thus reducing the windows of mass tolerance and increasing the confidence of identification. This proteomic approach revealed expression of 72 nucleic acid-binding proteins. SWISS-PROT accession numbers and names of the analyzed proteins with MALDI information are given in Table II . Identified proteins are subgrouped into different categories based on their possible functions as DNA handling, RNA Table III .
Results
To
Proteomic analysis revealed variable expression of nucleic acid-binding proteins ranging from cell line-specific expression through expression limited to few cell lines to expression by multiple cell lines. About 45.8% of the total identified proteins were expressed only in one cell line, 41.7% in 2-5 cell lines, and 12.5% in 6-10 cell lines, representing tumor-specific, moderate tumor-associated and tumor-associated expression, respectively. Moreover, some proteins were represented by more than one spot. Three spots were detected for elongation factor 2 in CaOva3; three spots for heterogeneous nuclear ribonucleoprotein (hnRNP) C1/C2 in HL-60; two spots for lupus La protein in SK-N-SH, hnRNP A2/B1 in HeLa cervix, far upstream element binding protein (FAB) 1 in A-375 and MCF-7, eEF2 in SK-N-SH, and RuvB-like 1 in MCF-7. The different spots may represent different expression forms of the same protein, as post-translational modification is a common theme in protein biochemistry.
RNA handling proteins involved in splicing, transport, translation or degradation accounted for 76% and 69% of the total proteins identified and tumor-specific protein expression, respectively. RNA handling proteins involved in translation constituted the largest proportion of proteins that exhibited tumor-specific expression. This was followed by the hnRNPs that take part in pre-mRNA splicing and transport of the mature mRNA. Among the seven identified aminoacyl-tRNA synthetases, whilst six of them were expressed only in MCF-7 cell line, tryptophanyl-tRNA synthetase was detected in multiple cell lines. In stark contrast, hnRNPs expression was fairly distributed amongst cell lines. Only hnRNPs: A1, A3, F, R and M showed cell specific expression.
DNA handling proteins involved in transcription, replication or repair constituted about 18% of the total proteins identified. Not unlike the translational proteins, the transcriptional machinery proteins, notably transcription factors were the major DNA handling proteins that displayed tumor-specific expression. There was, however, little or no tumor-associated expression of DNA handling proteins, since FBP1 was the only protein that displayed expression in four cell lines. DNA handling proteins whose role in cancer is not known, such as 
MCF-7
A-673
Hela-cervix Table II . Mass spectroscopical identification of nucleic acid binding proteins in ten different investigated tumor cell lines (+, detected; -, undetected; each + represents one spot). Table II . Continued. THO complex subunit 3 (expressed in MCF-7) and DNA handling proteins including XAP-5 protein (expressed in A-549 cell line), both zinc finger protein 431 and zinc finger protein 24 (only in A-673) were identified.
Proteins grouped under miscellaneous include proteins that bind to DNA and RNA as well as those that may not have direct nucleic acid-binding activity, but contribute to the handling of nucleic acids indirectly for e.g., through binding to the nucleic acid-binding proteins. Such proteins accounted for 13.9% of the total identified proteins, out of which non-POU domain-containing octamer-binding protein, 40S ribosomal protein S9; chromobox protein homolog 5; NRASrelated protein and ribosomal protein L13 exhibited cell line specificity. Although proteins that bind to both DNA and RNA are grouped under miscellaneous (Table II) , the poly (rc) binding protein family, including poly (rc) binding protein 1 (hnRNP E1) and hnRNP K are discussed under RNA binding proteins for purpose of simplicity. 
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Saos-2, bone osteosarcoma; SK-N-SH, brain neuroblastoma; HCT116, adenocarcinoma of colon; CaOva3, adenocarcinoma of ovary; A-549: alveolar cell carcinoma of lung; HL-60, peripheral blood, promyelocyte leukaemia; A-375, skin malignant melanoma; A-673, muscle rhabdomyosarcoma; MCF-7, breast cancer; HeLa cervix, cervix adenocarcinoma. a Theoretical molecular weight. b Theoretical isoelectric point; Mascot-search-MS-results: c observed molecular weight, d total score, e number of matched peptides. Table III . Results of domain analysis of nucleic acid binding proteins in ten tumor cell lines.
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Q07955
Splicing factor, arginine/ SFRS1 2 RRM ---serine-rich 1
P84103
Splicing factor, arginine/ SFRS3 1 RRM ---serine-rich 3
P23246
Splicing factor, proline-SFPQ 2 RRM ---and glutamine-rich
Q13435
Splicing factor 3B F3B2 -DNA-binding -Protein of unknown function DUF382 subunit 2 SAP IPR007180 (after SAF-A/B, PSP, proline-rich domain Acinus and PIAS) IPR006568 IPR003034
Q96J01
THO complex THOC3 ---6 WD repeat subunit 3 Table III . Continued. Table III . Continued. -
a Protein families database of alignments and HMMs. b InterPro database.
-
Discussion
Expression of genes, including those involved in carcinogenesis is regulated at many different levels: transcription, mRNA processing and transport, mRNA degradation, and translation of mRNA to synthesize the protein it is encoded for, and nucleic acid-binding proteins play a major role in this regard. This report explored the use of proteomics as a tool for identifying tumor-specific and/or tumor-associated expression of nucleic-acid handling proteins that could serve as diagnostic biomarkers or therapeutic targets in a widerange of cell lines used by the scientific community. In the present comprehensive study, we hereby demonstrate cellline specific expression of 32 proteins, which may represent the well-defined phenotype of the individual cell lineages and cell type specific functions.
RNA handling proteins. Since gene expression is regulated during further processing of pre-mRNA into mRNA that is ready to be translated in the cytosol, proteins that bind to RNA during processing may thus be involved in controlling gene expression. One such well-characterized group is the SR family of proteins, which are splicing regulatory proteins that among other properties bind to exonic splicing enhancer sequences (11) . Specific phosphorylation of SR proteins is one of the key determinants regulating splicing events and antitumor drugs, such as indolocarbazoles have been shown to act by inhibiting SR phosphorylation (12) . Tumor-associated expression of splicing factor SR1 and cell line-specific expression of SR3 in HeLa cell suggest that different tumors might differentially regulate each member of a protein family and this might help in defining different tumor types. Another less-well characterized group of pre-mRNA binding proteins are hnRNPs where about 30 have been identified so far and function in a staggering array of cellular activities, ranging from transcription and pre-mRNA processing in the nucleus to cytoplasmic mRNA translation and turn over (13) . An accumulating body of evidence indicates that hnRNPs are implicated in tumorigenesis. In BCR/ABL leukemogenesis, hnRNP A1 and hnRNP E2 proteins are upregulated via posttranslational mechanism that resulted in enhanced protein stability (14) . hnRNP C1/C2, hnRNP E1 and hnRNP K (the later two bind both RNA and DNA) have been shown to bind and enhance translation at the internal ribosomal entry site element of c-myc, with hnRNP C1/C2 binding at the 367-411 nucleotide region and hnRNP E1 and hnRNP K at 158-211 nucleotide region (15, 16) . Moreover, expression of hnRNP K is up-regulated in grade III breast cancer samples and this upregulation appears to correlate with anchorage-independence and enhanced proliferation of breast cancer cells (17) . hnRNP F and hnRNP H/H', which belong to a subgroup of hnRNPs characterized by a special structure of the RRM domains that consequently have been denoted as quasi-RRM domains, are differentially regulated in a variety of tumors (11) . The observation that all-trans-retinoic-acid inducing growth inhibition, differentiation, and apoptosis; down-regulated a number of hnRNPs in acute promyelocytic leukemia (18) strongly reinforces the importance of hnRNPs in cancer. Given the role of hnRNPs in tumor biology, it is not surprising to see a fair distribution of hnRNPs in the cell lines investigated.
This suggests that while some hnRNPs (for e.g., A1, A3, H3, F, Q and R) could possibly serve as a specific-marker for a specific tumor, others (such as, C1/C2, A2/B1, A/B, E1, H/H', K and L) may be used as a general marker for tumor development. Lupus La protein plays a role in stabilization of nascent transcripts of RNA polymerase III and is shown to increase expression of mdm2, a negative regulator of p53, in BCR/ABL expressing cells (19) . Lupus La protein expressed in three cell lines, and ribonucleoprotein (fragment), which is specifically expressed in HCT116 and has a lupus La domain, are among candidate proteins with possible modulatory role in tumorigenesis.
The process of translation is very complex and involves several translational factors that control the three distinct steps of translation i.e., initiation, elongation and termination. Regulation of gene expression at the level of translation has attracted much attention particularly in relationship to cancer following the observation that disruption by mutation or overexpression of translational factors can cause cellular transformation (20) . Since then, a number of studies have been published showing that alteration in expression of, notably overexpression of eIF2 and eIF4 translational factors is often associated with human carcinogenesis (21) (22) (23) (24) (25) . Inspite of the evidence implicating the involvement of certain translation factors in neoplastic developments, the underlying mechanisms responsible for their oncogenic potential are less well understood. Several translation factors, including seven initiation and four elongation factors have been identified in the present study. Although no direct link of the identified factors and cancer exists in the literature, there are few candidates that may be considered as relevant for tumor biology for e.g., eEF2. eEF2 is phosphorylated by eEF2-kinase, whose activity is increased in several malignancies and non-specific inhibitors of this enzyme promoted cell death (26) .
Aminoacyl-tRNA synthetases catalyze activation of amino acids and their subsequent linkage to tRNAs, a process that simplifies the difficulty of formation of peptide bond between two amino acids and codon recognition. A finding that appears to be of significance is that expression of nearly all identified aminoacyl-tRNAs was restricted to MCF-7 cell line, tryptophanyl-tRNA synthetase being an exception, which was expressed in three cell lines. At this juncture, we cannot explain exactly why most aminoacyl-tRNA synthetases concentrated in one cell line. However, it seems that MCF-7 cell line largely expresses class II synthetases and all the rest class I synthetases, the exception being tyrosyl-tRNA synthetase, a class I enzyme expressed by the MCF-7 cell line. This finding suggests that class II enzymes that activate smaller amino acids are potential markers for breast cancer better than class I that activates larger and also more hydrophobic amino acids.
DNA handling proteins. Initiation, progression and maintenance of some tumors depends upon overexpression through gene amplification or inappropriate expression of normal genes, mutation in a critical region of a gene, or impaired responses to DNA damage. Transcription activator and repressor proteins that regulate gene expression by altering the rate of formation of the transcriptional apparatus, and proteins involved in the DNA repair pathways thus have an important role in tumorigenesis. A number of DNA handling proteins, which have already been implicated in tumor biology have been identified in the investigated cell lines. Replication protein A 32 kDa, expressed only in the HeLa cell line, is a heterotrimeric protein required for DNA replication, recombination and repair, and has been found to interact with menin, a protein encoded by the tumor suppressor gene, MEN1 (27) . Transcription intermediary factor ß-1, expressed only in SK-N-SH cell line, specifically interacts with the Kruppel-associated box (KRAB) domain of the human zinc finger factor and corepresses transcription (28) . Although transcription intermediary factor ß-1 per se is not linked to cancer, KRAB-related domains are shown to be disrupted in human sarcomas (29) . Nuclear protein Hcc-1, a protein expressed in MCF-7, is a cytokine regulated protein whose overexpression enhances cell proliferation in normal as well as cancer cells (30) . Transcription factor BTF3, expressed in CaOva3 and A-549; was found to be altered in human Burkitt lymphoma cell line induced to undergo apoptosis (31) . FAB1 (32) and RuvB-like 2 (33), which showed broader expression are also important in c-myc oncogenic transformation by binding to single stranded DNA. DNA repair protein RAD50 is one of several recombination repair genes that are required for mitotic repair of DNA damage induced by irradiation. Human RAD50 gene is shown to have two splice variants denoted as RAD50-2 and RAD50-3 (33). The RAD50-3 splice variant has a deduced open reading frame encoding a 1173 amino acid protein with a molecular size of 138 kDa dubbed as truncated RAD-50 protein. Database search (www.expasy.org/tools/sim-prot/html) revealed that truncated RAD50 protein has 100% identity to RAD50-2 from amino acid sequence 140-1312 and 99.4% identity to RAD-50 homologue hsRAD50 (RAD50-1) from amino acid sequence 146 to 1318. Truncated RAD50 lacks the N-terminal ATP-binding domain, which is important for DNA-binding activity of RAD-50 proteins (34, 35) . Thus, cells expressing truncated RAD50 protein may have defective DNA-repair capacity, indicating the importance of this protein in genetic instability and tumor biology. Another one is zinc finger protein 431, a protein with KRAP and zinc-finger domains and is expressed in A-673. Zinc-finger proteins bearing this domain are shown to be overexpressed in pancreatic carcinoma (37) and serve as transcriptional repressor proteins (29) . XAP-5, expressed in A-549 cell line, is encoded by a gene located on Xq28 (38) and contains a XAP-5 domain whose function is uncertain and thought to bind DNA. Taken together, these findings suggest that DNA handling proteins not only be potential diagnostic markers but also treatment targets.
Miscellaneous proteins. Chromobox proteins recognize and bind to histone H3 tails methylated at Lys-9 and seem to be involved in transcriptional silencing through formation of heterochromatin-like complexes. These proteins are demonstrated to be recruited by the KRAP-ZFP-KAP1 complex in gene silencing (38) . Since KRAP-like domains are implicated in cancer (28) , the involvement of chromobox proteins in cancer is highly likely. Moreover, the limited expression of chromobox protein homolog 3 and 5 in HL-60 and HeLa cell may endow them to be a potential therapeutic avenue for solid tumors. Ribosome-binding protein-1 is an uncharacterized protein thought to act, by similarity, as a ribosome receptor and mediates interaction between the ribosome and the endoplasmic reticulum. The sole expression of this protein in A-375 cell line and its supposed involvement in protein synthesis and sorting calls for further investigation.
In summary, the data demonstrated cell-line specific expression of nucleic acid-binding proteins, which play an essential role in maintenance of the cellular integrity of a multicellular organism through regulation of gene expression. The proteins identified may have future clinical relevance for preventative, diagnostic and therapeutic purposes. Particularly, the protein synthetic machinery represents an attractive target for cancer therapy, since it is activated by a variety of genetic alteration during tumor progression. However, further validation of these findings with several cell lines and human tumor samples is required prior to probable use of these proteins as potential molecular markers or targets in human cancer. A handful of the structures described herein have been also reported in normal cell lines by this protein chemical technique independent of antibody availability and specificity (39) (40) (41) .
